Pharsight

AMGEN INC PATENTS FACING OPPOSITIONS

Top patents of AMGEN INC facing oppositions at the European Patent Office (EPO)

Patent Number Grant Date Patent Title Expected Expiration Date Facing Oppositions Activity Alert
EP3395339B8 11 Dec, 2019 Rapid Dissolution Formulation Of A Cinacalcet Hcl Sep, 2024 11
EP3395340B8 11 Dec, 2019 Rapid Dissolution Formulation Of Cinacalcet Hcl Sep, 2024 9
EP3260117B8 27 Nov, 2019 Rapid Dissolution Formulation Of A Calcium Receptor-Active Compound Sep, 2024 8
EP3578175B1 30 Nov, 2022 Rapid Dissolution Formulation Of A Calcium Receptor-Active Compound Sep, 2024 7
EP3395338B1 01 May, 2019 Rapid Dissolution Formulation Of Cinacalcet Hcl Sep, 2024 7
EP3246017B1 24 Mar, 2021 Stable Liquid Formulation Of Amg 416 Hcl (Etelcalcetide) Jun, 2034 4
EP2382228B1 26 Aug, 2020 Compositions And Methods Of Treating Inflammatory And Autoimmune Diseases Jan, 2030 4
EP3681483B1 18 May, 2022 Process For Lyophilized Pharmaceutical Formulation Of A Therapeutic Protein Sep, 2038 3
EP3666797B1 17 May, 2023 Antigen Binding Proteins To Proprotein Convertase Subtilisin Kexin Type 9 (Pcsk9) Aug, 2028 2
EP3658203B1 31 Aug, 2022 Drug Delivery Device With Gear Module And Related Method Of Assembly Jul, 2038 2
EP3464277B1 28 Dec, 2022 Pegylated Carfilzomib Compounds May, 2037 1
EP3381942B1 14 Apr, 2021 A Method For Treating Melanoma Using A Herpes Simplex Virus And An Immune Checkpoint Inhibitor Aug, 2033 1
EP3085386B1 24 Jun, 2020 Method For Inhibiting Bone Resorption Sep, 2028 1
EP2641917B1 06 May, 2020 Antigen Binding Proteins To Proprotein Convertase Subtilisin Kexin Type 9 (Pcsk9) Aug, 2028 1